3 documents found, page 1 of 1
Diagnosis and management of acromegaly: a consensus statement of the pituitary ...
Cardoso, Luís Miguel; Marques, Pedro; Pereira, Maria Teresa; Agapito, Ana; Almeida, Rui; Amaral, Sara; Cattoni, Maria Begona; Bugalho, Maria JoãoAcromegaly is characterised by hypersecretion of growth hormone and presents diagnostic and therapeutic challenges that require consensus and guidelines for effective management. The Pituitary Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism used a modified Delphi methodology to develop consensus recommendations for the diagnosis and management of acromegaly. A multidisciplinary p...
Case Report: Pheochromocytoma and Synchronous Neuroblastoma in a Family With He...
Duarte, Diana Borges; Ferreira, Lia; Santos, Ana P.; Costa, Cláudia; Lima, Jorge; Santos, Catarina; Afonso, Mariana; Teixeira, Manuel R.; Carvalho, RuiIntroduction: Pheochromocytomas are rare catecholamine-producing neuroendocrine tumours arising from chromaffin cells of the adrenal medulla or extra-adrenal sympathetic paraganglia. Recent studies have indicated that up to 40% of pheochromocytomas could be attributable to an inherited germline variant in an increasing list of susceptibility genes. Germline variants of the MYC-associated factor (MAX) gene have ...
Graves’ disease with spontaneous resolution following ocrelizumab in primary pr...
Duarte, Diana Borges; Silva, Ana Martins; Freitas, Claudia; Cardoso, HelenaObjectives. Immune reconstitution therapies (IRT), which include antibody-based cell-depleting therapies targeting CD52+ (alemtuzumab) or CD20+ (rituximab, ocrelizumab) leukocytes, are approved for the treatment of multiple sclerosis. Thyroid autoimmunity is a common adverse effect of alemtuzumab treatment, Graves' disease (GD) being the most prevalent manifestation. To date, thyroid autoimmunity events have no...